Identification of microRNA biomarker candidates in urine and plasma from rats with kidney or liver damage

Francis S Wolenski1, Pooja Shah2, Tomoya Sano3

  • 1Drug Safety Research & Evaluation, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, USA.

Insights

MicroRNAs (miRNAs) in urine and plasma can serve as novel biomarkers for detecting specific organ damage. This study used next-generation sequencing to identify altered miRNA levels following toxicant exposure in rats.

Area of Science:

  • Biomarkers
  • Toxicology
  • Molecular Biology

Background:

  • MicroRNAs (miRNAs) regulate gene expression post-transcriptionally.
  • Tissue-specific miRNAs hold potential as safety biomarkers.
  • Detecting miRNA changes in biofluids can indicate tissue damage.

Purpose of the Study:

  • To investigate the utility of plasma and urine miRNAs as biomarkers of organ injury.
  • To analyze miRNA profile changes in response to specific toxicants (cisplatin, acetaminophen, carbon tetrachloride).

Main Methods:

  • Utilized next-generation sequencing (miR-seq) to analyze miRNA profiles.
  • Examined miRNA changes in kidney, liver, plasma, and urine samples from treated rats.
  • Correlated miRNA alterations with traditional serum chemistry and histopathology findings.

Main Results:

  • Specific organ damage was confirmed by traditional methods.
  • Cisplatin treatment altered miRNAs in kidney, plasma, and urine (e.g., miR-378a in urine).
  • Hepatotoxicant treatments (APAP, CCl4) showed common plasma miRNA elevations, including liver-enriched miR-122 and miR-802.

Conclusions:

  • Comparative analysis of urine and plasma miRNAs demonstrates their effectiveness as biomarkers for organ injury.
  • Identified specific miRNAs (e.g., miR-378a, miR-122, miR-802) as indicators of kidney and liver damage, respectively.
  • miRNA profiling in biofluids offers a sensitive approach for detecting toxicant-induced organ damage.

Related Concept Videos